Bell Potter Reaffirms Their Buy Rating on Trajan Group Holdings Ltd (TRJ)
In a report released today, Martyn Jacobs from Bell Potter maintained a Buy rating on Trajan Group Holdings Ltd (TRJ – Research Report), with a price target of A$1.50.
Confident Investing Starts Here:
Jacobs covers the Healthcare sector, focusing on stocks such as EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh, Trajan Group Holdings Ltd, and Medical Developments International Limited. According to TipRanks, Jacobs has an average return of -21.3% and a 13.92% success rate on recommended stocks.
Trajan Group Holdings Ltd has an analyst consensus of Moderate Buy, with a price target consensus of A$1.53.
The company has a one-year high of A$1.31 and a one-year low of A$0.72. Currently, Trajan Group Holdings Ltd has an average volume of 29.48K.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
41 minutes ago
- Business Upturn
IOVA FRAUD ALERT: Iovance Biotherapeutics Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by July 14 Legal Deadline (NASDAQ:IOVA)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Iovance you are encouraged to obtain additional information by visiting Investors have until July 14, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Iovance securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sundaram v. Iovance Biotherapeutics, Inc., et al. , No. 25-cv-04177. Why was Iovance Sued for Securities Fraud? Iovance is a commercial-stage biopharmaceutical company focused on the development of treatments for melanoma and other solid tumor cancers. The Company commercially launched its key melanoma treatment Amtagvi in February 2024. Iovance administers Amtagvi at the Company's authorized treatment centers ('ATCs'). As alleged, Iovance repeatedly touted its ATCs as a driver of demand for Amtagvi. In truth, Iovance's ATCs were experiencing long timelines to begin treating patients with Amtagvi, and ineffective patient identification and patient selection for treatment was causing high patient drop-offs at the ATCs. The Stock Declines as the Truth is Revealed On May 8, 2025, Iovance reported disappointing financial results for 1Q25 and announced it was 'revising full-year 2025 revenue guidance.' The Company blamed 'recent launch dynamics,' including slow 'treatment timelines for new ATCs' and 'the variable pace at which ATCs began treating patients,' which 'differs from center to center.' Iovance also blamed the poor results on high 'patient drop-off' due to inadequate 'patient selection' for treatment. On this news, the price of Iovance stock declined more than 44%, from $3.17 per share on May 8, 2025, to $1.75 per share on May 9, 2025. Click here if you suffered losses: What Can You Do? If you invested in Iovance you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Upturn
42 minutes ago
- Business Upturn
FTRE FRAUD ALERT: Fortrea Holdings Inc. Investors are Reminded of Ongoing Securities Fraud Class Action — Contact BFA Law by August 1 Legal Deadline (NASDAQ:FTRE)
NEW YORK, June 22, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting Investors have until August 1, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Fortrea securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned Deslande v. Fortrea Holdings Inc., et al. , No. 1:25-cv-04630. Why was Fortrea Sued for Securities Fraud? Fortrea is a global contract research organization that provides biopharmaceutical product and medical device development solutions. In June 2023, Fortrea was spun off into a standalone, publicly traded company by Labcorp Holdings Inc. ('Labcorp'). In connection with the spin-off, Fortrea entered into several transition services agreements (the 'TSAs'), pursuant to which it agreed to pay Labcorp for certain transitional services over a set period. As alleged, Fortrea discussed the significant cost savings and margin improvements that would result from exiting the TSAs. In truth, Fortrea overstated the cost savings and margin improvement it would achieve by exiting the TSAs, as well as the amount of revenue it would generate from pre-spin projects. The Stock Declines as the Truth is Revealed On September 25, 2024, investment bank Jefferies published a report stating that the cost savings Fortrea would achieve from exiting the TSAs were '[n]ot as [m]aterial as [o]ne [m]ight [t]hink.' On this news, the price of Fortrea stock declined $2.73 per share, or over 12%, from a closing price of $22.21 per share on September 24, 2024, to $19.48 per share on September 25, 2024. Then, on March 3, 2025, Fortrea announced disappointing Q4 and full year 2024 financial results, revealing that the company's pre-spin projects 'have less revenue and less profitability than expected for 2025' and that 'post-spin work is not coming on fast enough to offset the pre-spin contract economics.' On this news, the price of Fortrea stock declined $3.47 per share, or over 25%, from a closing price of $13.85 per share on February 28, 2025, to $10.38 per share on March 3, 2025, the next trading day. Click here if you suffered losses: What Can You Do? If you invested in Fortrea you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Business Insider
an hour ago
- Business Insider
Iran Strike Shakes Markets: Where Smart Investors Are Moving Their Portfolios Now
Investors are preparing for market turbulence after the U.S. launched a military strike on Iranian nuclear sites. The move, announced by former President Donald Trump on Truth Social and described as a 'spectacular military success,' adds new uncertainty to an already fragile global outlook. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Oil prices are expected to spike when markets reopen. Brent crude is already up 18% since June 10, closing at $77.37 per barrel on Friday. Analysts at Oxford Economics warn that if Iranian oil production is disrupted or the Strait of Hormuz is closed, crude could surge to $130 per barrel. That would push U.S. inflation toward 6% by year-end, sharply reducing the chances of Federal Reserve rate cuts in 2025. Which Stocks Are Set to Benefit Higher oil costs may boost energy stocks like ExxonMobil (XOM), Chevron (CVX), and Schlumberger (SLB), but could weigh on consumer-facing sectors. Airlines such as Delta Airlines (DAL) and United Airlines (UAL) may feel margin pressure, while retailers like Target (TGT) and Walmart (WMT) could see demand soften as fuel prices cut into household budgets. Safe-haven demand is likely to lift the U.S. dollar and Gold (XAUUSD). The dollar has been under pressure for most of the year, but geopolitical tension tends to drive inflows into U.S. assets. Treasury yields may fall if investors rush into bonds, while gold prices could benefit from risk aversion. Equities typically decline following major military escalations but often rebound in the months that follow. According to Wedbush Securities, the S&P 500 (SPY) has averaged a 2.3% gain two months after the start of previous Middle East conflicts, despite initial losses. Defense contractors may be another area of interest. Traditional defense stocks, such as Lockheed Martin (LMT) and RTX Corporation (RTX), could attract attention if military engagement continues or expands, but Palantir (PLTR) might also see further contracts being struck. No One Likes Uncertainty The bigger question is how long the uncertainty lasts. A quick resolution could limit damage to markets and ease pressure on inflation. But a prolonged standoff or disruption to oil flows would complicate the Fed's path and keep volatility elevated. For now, investors should closely monitor key indicators, including oil prices, bond yields, gold, and the U.S. dollar. These will signal whether risk sentiment is stabilizing or deteriorating. Diversification into energy and defense may provide a cushion, while keeping some exposure to gold and cash-like assets could help manage volatility. Market reactions to geopolitical shocks often evolve quickly. The key is staying informed and being ready to adjust. We used TipRanks' Co mparis on Tool to bring together all the energy, defense, and retail stocks mentioned above, giving you a broader view of each company and how it stacks up within its industry.
